Literature DB >> 4088625

Gyrate atrophy of the choroid and retina. A five-year follow-up of creatine supplementation.

K Vannas-Sulonen, I Sipilä, A Vannas, O Simell, J Rapola.   

Abstract

Gyrate atrophy of the choroid and retina (GA) is an autosomal recessive chorioretinal degeneration with a 10-20-fold elevation of plasma ornithine due to deficient activity of ornithine aminotransferase. Type II fibres of the skeletal muscle are atrophic and contain tubular aggregates in electron microscopy. Deficient creatine and creatine phosphate formation have been postulated to be involved in the pathogenesis of GA. The five-year follow-up results of oral creatine supplementation in 13 patients are presented. Visual function tests and fundus photographs showed progression of GA during the treatment. The velocity of the progression varied considerably between individuals. Generally, the progression was rapid in the young patients and slow in the more advanced stages. Abnormalities in the skeletal muscle decreased or disappeared rapidly. They reappeared in the few patients who discontinued the medication. The difference in the therapeutic effect on the skeletal muscle and eye is discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4088625     DOI: 10.1016/s0161-6420(85)34098-8

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  16 in total

1.  Creatine supplementation during college football training does not increase the incidence of cramping or injury.

Authors:  Michael Greenwood; Richard B Kreider; Charlie Melton; Christopher Rasmussen; Stacy Lancaster; Edward Cantler; Purvis Milnor; Anthony Almada
Journal:  Mol Cell Biochem       Date:  2003-02       Impact factor: 3.396

2.  Long-term creatine supplementation does not significantly affect clinical markers of health in athletes.

Authors:  Richard B Kreider; Charles Melton; Christopher J Rasmussen; Michael Greenwood; Stacy Lancaster; Edward C Cantler; Pervis Milnor; Anthony L Almada
Journal:  Mol Cell Biochem       Date:  2003-02       Impact factor: 3.396

Review 3.  Oral creatine supplementation and skeletal muscle metabolism in physical exercise.

Authors:  José L M Mesa; Jonatan R Ruiz; M Marcela González-Gross; Angel Gutiérrez Sáinz; Manuel J Castillo Garzón
Journal:  Sports Med       Date:  2002       Impact factor: 11.136

4.  Osteoporosis associated with gyrate atrophy: a case report.

Authors:  Isik Ahmet; Koca Suleyman Serdar
Journal:  Doc Ophthalmol       Date:  2006-08-12       Impact factor: 2.379

5.  Central nervous system involvement in gyrate atrophy of the choroid and retina with hyperornithinaemia.

Authors:  M Valtonen; K Näntö-Salonen; S Jääskeläinen; K Heinänen; A Alanen; O J Heinonen; N Lundbom; M Erkintalo; O Simell
Journal:  J Inherit Metab Dis       Date:  1999-12       Impact factor: 4.982

Review 6.  Pharmacokinetics of the dietary supplement creatine.

Authors:  Adam M Persky; Gayle A Brazeau; Günther Hochhaus
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Gyrate atrophy of the choroid and retina with hyperornithinemia, cystinuria and lysinuria responsive to vitamin B6.

Authors:  Fatos Tanzer; Mehtap Firat; Meral Alagoz; Haydar Erdogan
Journal:  BMJ Case Rep       Date:  2011-03-15

8.  Gyrate atrophy: clinical and genetic findings in a female without arginine-restricted diet during her first 39 years of life and report of a new OAT gene mutation.

Authors:  Agnes B Renner; Andreas Walter; Britta S Fiebig; Herbert Jägle
Journal:  Doc Ophthalmol       Date:  2012-06-07       Impact factor: 2.379

Review 9.  Creatine in humans with special reference to creatine supplementation.

Authors:  P D Balsom; K Söderlund; B Ekblom
Journal:  Sports Med       Date:  1994-10       Impact factor: 11.136

10.  Anti-inflammatory activity of creatine supplementation in endothelial cells in vitro.

Authors:  Akihiro Nomura; Minjie Zhang; Tohru Sakamoto; Yukio Ishii; Yuko Morishima; Mie Mochizuki; Toru Kimura; Yoshiyuki Uchida; Kiyohisa Sekizawa
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.